Brokerages predict that Xencor Inc (NASDAQ:XNCR) will announce earnings per share of $0.43 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Xencor’s earnings, with the highest EPS estimate coming in at $1.37 and the lowest estimate coming in at ($0.24). Xencor posted earnings per share of ($0.62) during the same quarter last year, which suggests a positive year over year growth rate of 169.4%. The business is scheduled to report its next earnings results on Monday, May 6th.

According to Zacks, analysts expect that Xencor will report full-year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($1.90) to $0.18. For the next year, analysts forecast that the business will report earnings of ($1.03) per share, with EPS estimates ranging from ($2.80) to ($0.10). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Xencor.

Several research analysts have commented on XNCR shares. Raymond James started coverage on Xencor in a research report on Thursday, March 14th. They set an “outperform” rating and a $40.00 price target on the stock. Zacks Investment Research upgraded shares of Xencor from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research note on Saturday, December 1st. BidaskClub cut shares of Xencor from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. Nomura cut shares of Xencor from a “neutral” rating to a “reduce” rating and dropped their target price for the company from $28.00 to $21.00 in a research note on Friday, February 22nd. Finally, Piper Jaffray Companies boosted their target price on shares of Xencor to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, February 26th. Two investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. Xencor currently has a consensus rating of “Buy” and a consensus target price of $41.78.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its position in shares of Xencor by 46.9% in the fourth quarter. Meeder Asset Management Inc. now owns 2,910 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 929 shares during the period. Tower Research Capital LLC TRC bought a new stake in shares of Xencor in the third quarter valued at approximately $142,000. Gotham Asset Management LLC bought a new stake in shares of Xencor in the fourth quarter valued at approximately $240,000. Amalgamated Bank bought a new stake in shares of Xencor in the fourth quarter valued at approximately $248,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Xencor in the fourth quarter valued at approximately $339,000. 83.32% of the stock is currently owned by institutional investors.

XNCR stock traded down $0.02 during trading on Tuesday, hitting $30.40. 57,759 shares of the company’s stock were exchanged, compared to its average volume of 278,807. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -23.21 and a beta of 1.40. Xencor has a 52-week low of $27.57 and a 52-week high of $48.38.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Further Reading: QQQ ETF

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.